Irlab Therapeutics
IRLAB Therapeutics AB is a Swedish clinical-stage biopharmaceutical company focused on treatments for Parkinson's disease and neurodegenerative disorders. The company discovers and develops drug candidates using its proprietary Integrative Screening Process technology platform, advancing lead candidates including mesdopetam and pirepemat. Main revenue drivers currently consist of strategic pharmaceutical research collaborations, milestone grants, licensing fees, and equity financing as clinical trials progress. IRLAB Therapeutics targets clinical research institutions, neurology specialists, global pharmaceutical partners, and Parkinson's disease patients across Europe and North America. The company holds a specialized niche position in Swedish CNS drug discovery and neurodegenerative disease research. Headquartered in Gothenburg, Sweden, IRLAB Therapeutics AB is listed on Nasdaq Stockholm.
2 of the funds FundTelligence covers report a position in Irlab Therapeutics.
- Legal name
- Irlab Therapeutics AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
- Exposure themes
- Ageing & Longevity, Age-Related Disease, Neurodegeneration
Funds holding Irlab Therapeutics
- Storebrand Sverige Småbolag Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)